#NNVC

NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position NanoViricides (NYSE Amer.: NNVC) filed its Form 10-Q for the quarter ended September 30, 2025 and reported clinical and financing updates for its lead candidate NV-387.Key financials as of 9/30/2025: $1.25M cash, $8.36M total assets (including $6.78M net P&E), and $1.18M current liabilities. Net cash used in Q3 was $1.59M.Subsequent financings raised ~$6.1M (cash added as of 11/12/2025), including a $5.5M registered direct/private placement on 11/10/2025, plus ATM proceeds and a $3M founder line of credit. Company states runway is not sufficient to fund operations through Feb 14, 2026 without additional financing.

3 months ago

#NNVC NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position

www.stocktitan.net/news/NNVC/nano-viricides...

0 0 0 0

NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close NanoViricides (NYSE American: NNVC) announced a registered direct offering of 3,571,429 shares at $1.68 per share for gross proceeds of approximately $6.0 million, expected to close on or about November 12, 2025, subject to customary conditions.Concurrently the company will issue Series A warrants (exercise $1.75, exercisable after 6 months, 2‑year term) and Series B warrants (exercise $2.00, exercisable after 6 months, 5.5‑year term) to purchase up to 3,571,429 shares each. The Series B exercise price is ~20% premium to the Nov 10, 2025 closing price. Net proceeds are intended for working capital and general corporate purposes. A.G.P./Alliance Global Partners is sole placement agent.

4 months ago

#NNVC NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close

www.stocktitan.net/news/NNVC/nano-viricides...

0 0 0 0

4 months ago

NNVC: Phase 2 Trial of NV-387 Antiviral for Mpox | NanoViricides YouTube video by Zacks Investment Awareness

#NNVC NanoViricides is preparing for a Phase 2 trial of NV-387 for Mpox, expected to begin in late 2025 or early 2026. Results could set the stage for stockpile programs and broader antiviral use. #NanoViricides #BiotechStocks #Antivirals

youtu.be/7bJAJ82Dltc

0 0 1 0

4 months ago

#NNVC NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo

www.stocktitan.net/news/NNVC/nano-viricides...

0 0 0 0

4 months ago

#NNVC: Getting Set for Phase 2 Trial of NV-387 in MPox… buff.ly/OgH9tJy

0 0 0 0

@smcapstrategist.bsky.social

4 months ago

#NNVC NanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT

www.stocktitan.net/news/NNVC/nano-viricides...

0 0 0 0

Small Cap Strategist

4 months ago

Most Searched, Monday November 3, 2025 – Crystal Equity Research

Most searched small-cap stocks, Mon Nov 3rd - #LAES #QURE #NVTS #TERN #SLDP #THAR #RXRX #AREC #FUBO #DVLT #CRBU #NVAI #ONDS #RR #PHIO #WRD #PLUG #BBAI #NNVC #CRML - More: crystalequityresearch.com/most-searche... - #smallcap

0 0 0 0

In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides NanoViricides (NYSE American: NNVC) announced that its lead candidate NV-387 showed strong antiviral activity against Measles in cell culture and a humanized lethal mouse model, increasing median survival to 17 days from 7.4 days (a 130% increase).NV-387 treatment correlated with slower disease progression, reduced lung plaques, and lower lung infiltration by lymphocytes and neutrophils. NV-387 completed Phase I with no reportable adverse events and is available as an oral gummy formulation. The company said Measles-specific development is not cost-effective and intends to seek non-dilutive grants while advancing NV-387 for multiple respiratory viruses.

4 months ago

#NNVC In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides

www.stocktitan.net/news/NNVC/in-treating-me...

0 0 0 0

NanoViricides, Inc. Has Filed its Annual Report Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage - NV-387 Could Become a Revolutionary Antiviral for Respiratory Viral InfectionsSHELTON, CONNECTICUT / ACCESS Newswire / September 30, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its

5 months ago

#NNVC NanoViricides, Inc. Has Filed its Annual Report

www.stocktitan.net/news/NNVC/nano-viricides...

0 0 0 0

A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials NanoViricides (NYSE:NNVC) reported that its broad-spectrum antiviral drug NV-387, which has completed Phase I clinical trials, could help reduce metastatic cancer resurgence triggered by viral infections. The drug's unique ability to reduce inflammation, particularly IL-6 cytokine levels, may prevent the reactivation of dormant cancer cells during viral infections.Research has shown that viral infections like COVID-19 and influenza can reawaken "sleeping" cancer cells, leading to metastasis. NV-387 has demonstrated superior effectiveness compared to existing treatments like Tamiflu, Rapivab, and Xofluza in protecting lungs during lethal viral infections in animal studies. The drug is being advanced to Phase II clinical trials for treating RSV, COVID, Long COVID, Influenza, and other respiratory viral infections. [ "NV-387 successfully completed Phase I clinical trials", "Drug demonstrates dual action: antiviral effects and inflammation reduction", "Superior lung protection compared to existing approved drugs in animal studies", "Broad-spectrum effectiveness against multiple viruses (RSV, COVID-19, Influenza)", "Potential new application in preventing cancer metastasis during viral infections" ]

6 months ago

#NNVC A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials

www.stocktitan.net/news/NNVC/a-drug-that-co...

0 0 0 0

Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides NanoViricides (NYSE:NNVC) announced that its drug candidate NV-387 could be crucial in fighting the increasing global measles cases. The drug has shown effectiveness against measles in animal studies and completed Phase I trials with no adverse events. NV-387 qualifies for Orphan Drug Designation and may be eligible for Fast Track designation, potentially accelerating its approval process.The company highlighted concerning measles statistics: 1,319 confirmed cases in the USA, 3,800 cases in Canada, and over 127,350 cases in the European Region in 2024. NV-387 addresses an unmet medical need, as there are currently no approved drugs for measles treatment, while vaccination rates struggle to maintain the required 95% coverage for herd immunity.

7 months ago

#NNVC Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides

www.stocktitan.net/news/NNVC/measles-cases-...

0 0 0 0

7 months ago

NNVC: NanoViricides Set to Initiate Phase 2 Trial in MPox YouTube video by Zacks Investment Awareness

A new antiviral class. A Phase 2 trial for deadly Mpox Clade I. A platform with multi-virus potential. #NNVC is one to watch.

youtu.be/ZvLpA9p8h9M

#NanoViricides #Biotech #SmallCapStocks #Antivirals #ClinicalTrials #Mpox #HealthcareInnovation

0 0 1 0

Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides NanoViricides (NYSE Amer: NNVC) has achieved a significant breakthrough in developing NV-387, potentially the first-ever drug treatment for Measles. In a humanized animal model study, NV-387 demonstrated strong effectiveness, increasing survival time by 130% (17 days vs. 7.4 days in untreated animals) with no toxicity signs.The broad-spectrum antiviral drug works by acting as a cell decoy, targeting 90-95% of human pathogenic viruses that require sulfated proteoglycan features. The study utilized specially modified mice bearing the human CD150/SLAM protein, necessary for measles infection. This development is particularly significant as global measles cases rise and vaccination rates decline, especially in industrialized nations.

7 months ago

#NNVC Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides

www.stocktitan.net/news/NNVC/measles-now-ha...

0 0 0 0

WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides NanoViricides (NYSE:NNVC) has responded to WHO's extension of the MPox Public Health Emergency status by highlighting the development of their drug candidate NV-387. The company is preparing for Phase II clinical trials of NV-387 for MPox treatment, following successful Phase I safety results where the drug showed no adverse events and demonstrated oral availability.Unlike current treatments Tecovirimat and Brincidofovir, which have shown limitations and safety concerns, NV-387 employs a unique host-mimetic nanomedicine technology that viruses reportedly cannot escape. The drug achieved a No-Observed-Adverse-Event Level at 1,200 mg/kg in animal studies and is formulated as oral gummies suitable for MPox patients with oral lesions.The company aims to target a multi-billion-dollar global market for poxvirus bioterrorism preparedness, particularly focusing on the US Strategic National Stockpile market upon successful Phase II trials.

7 months ago

#NNVC WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides

www.stocktitan.net/news/NNVC/who-extended-g...

0 0 0 0

8 months ago

#NNVC: NanoViricides Set to Initiate Phase 2 Trial in MPox buff.ly/SMyO93E

0 0 0 0

Adaptive Clinical Protocol Design for Phase II MPox Clade I Treatment with a Novel Broad-Spectrum Drug NV-387 is Almost Complete, Reports NanoViricides SHELTON, CT / ACCESS Newswire / July 14, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape,

8 months ago

#NNVC Adaptive Clinical Protocol Design for Phase II MPox Clade I Treatment with a Novel Broad-Spectrum Drug NV-387 is Almost Complete, Reports NanoViricides

www.stocktitan.net/news/NNVC/adaptive-clini...

0 0 0 0

With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan NanoViricides (NYSE: NNVC) announces that its broad-spectrum antiviral drug NV-387 could be crucial for pandemic preparedness amid rising COVID and bird flu variants. The drug has shown superior effectiveness against both COVID-19 and influenza compared to existing treatments like Remdesivir and Tamiflu. NV-387 has completed Phase I trials with no adverse events and is formulated as oral gummies. The drug targets invariant viral features, making it difficult for viruses to develop resistance. The company highlights NV-387's advantages including US-based manufacturing capabilities, room temperature storage, and potential rapid deployment for pandemic response. The drug's development comes as new COVID variant Nimbus (NB1.8.1) emerges with increased transmission and vaccine resistance, while H5N1 bird flu cases show concerning developments in Michigan and Cambodia.

8 months ago

#NNVC With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan

www.stocktitan.net/news/NNVC/with-rising-va...

1 0 0 0

NanoViricides Measles Drug Development Animal Study is Imminent NanoViricides (NYSE:NNVC) announces advancement in its Measles drug development program with an imminent animal trial using their clinical-stage drug NV-387. The study will use specially modified mice bearing human CD150/SLAM protein to evaluate drug candidates in a lethal infection model. NV-387, which previously demonstrated success in curing lethal RSV infection in animals, is designed to act as a cell decoy that destroys virus particles. This development comes amid rising measles cases, with 1,088 confirmed cases across 33 US jurisdictions in early 2025 and a ten-fold increase in European cases in 2024. The company aims to address an unmet medical need, as there are currently no approved drugs for measles treatment, while vaccination rates have declined below the 95% herd immunity threshold and vaccine failure cases are increasing due to new virus genotypes.

9 months ago

#NNVC NanoViricides Measles Drug Development Animal Study is Imminent

www.stocktitan.net/news/NNVC/nano-viricides...

0 0 0 0

NNVC - Nanoviricides Latest Stock News & Market Updates Nanoviricides Inc (NNVC) news hub: Track clinical trials, antiviral research updates, and corporate developments for this nanomedicine innovator. Official updates.

9 months ago

#NNVC The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan

www.stocktitan.net/news/NNVC/the-new-ration...

0 0 0 0

CanAm Stocks and Options

@wolfofstksoptn.bsky.social

9 months ago

$NNVC (NanoViricides, Inc.) is bouncing off key support with rising volume — a strong technical setup for a potential breakout. With its low float and renewed interest, this biotech sleeper could move fast. #Stocks #Biotech #NNVC

0 0 0 0

CanAm Stocks and Options

@wolfofstksoptn.bsky.social

9 months ago

$NNVC (NanoViricides, Inc.) is bouncing off key support with rising volume — a classic setup for a breakout play. The biotech firm’s novel nanomedicine platform could disrupt antiviral treatment. Technicals + potential catalysts make this a must-watch today. #Biotech #Stocks #NNVC

0 0 0 0

Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution NanoViricides (NYSE:NNVC) is advancing its broad-spectrum antiviral drug NV-387 to combat multiple viral threats. The company is targeting two major opportunities: Measles, where cases have increased 10-fold in Europe with concerning vaccine failure rates, and MPox, which remains a Public Health Emergency of International Concern according to WHO.The company has initiated an animal efficacy study for Measles and received clearance from DRC's National Ethics Committee to proceed with Phase II Clinical Trial for MPox treatment. NV-387 will be available to licensed physicians for treating Measles cases under FDA's Individual Patient Expanded Access protocol.Additionally, NanoViricides is developing NV-387 as an "emperic" treatment for respiratory viral infections through a "basket-type" clinical trial targeting All Influenzas, All Coronaviruses, and RSV. The company is also developing NV-HHV-1, a pan-herpesvirus drug targeting infections linked to neurological damage and Alzheimer's disease.

10 months ago

#NNVC Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution

www.stocktitan.net/news/NNVC/measles-cases-...

0 0 0 0

Broad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo NanoViricides (NYSE:NNVC) has received approval from the Democratic Republic of Congo's National Ethics Committee for Health to proceed with a Phase II clinical trial for NV-387, their broad-spectrum antiviral drug targeting MPox disease. The company is now preparing a detailed Clinical Trial Application for submission to DRC's Ministry of Public Health. NV-387 is designed to mimic human cells to trap and destroy viruses, potentially targeting 90-95% of human pathogenic viruses. The drug has shown promising results in animal studies against multiple viruses including influenza, RSV, coronavirus, and orthopoxvirus. Unlike existing treatments such as tecovirimat (which failed in clinical trials), NV-387's unique host-mimetic mechanism makes viral escape highly unlikely. This development is particularly significant as MPox continues to spread in the WHO African Region, maintaining its Public Health Emergency of International Concern status since August 2024.

10 months ago

#NNVC Broad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo

www.stocktitan.net/news/NNVC/broad-spectrum...

0 0 0 0

Biotech Pioneer NanoViricides Offers Exclusive One-on-One Meetings at Inaugural D. Boral Conference Learn about NanoViricides' breakthrough host-mimetic nanomedicine platform at the D. Boral Capital Conference. Schedule your private meeting with management. Get details.

10 months ago

#NNVC NanoViricides, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference, May 14th, NYC

www.stocktitan.net/news/NNVC/nano-viricides...

0 0 0 0

NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company NanoViricides (NYSE:NNVC) addresses recent stock price decline, emphasizing its immunity to tariffs and government spending cuts. The company's lead drug candidate, NV-387, is a broad-spectrum antiviral showing promise against multiple viruses including measles, RSV, MPox, and influenza.The company is preparing for a Phase II clinical trial of NV-387 for MPox treatment in Central Africa. NV-387's unique mechanism mimics host-side signatures that viruses target, potentially effective against 90% of human pathogenic viruses. The company also highlights NV-HHV-1, their herpesvirus antiviral candidate, and NV-HIV-1 for HIV/AIDS treatment.Management believes the recent stock decline alongside market sell-off is misguided, positioning NNVC as a potential hedge against market turmoil due to its strong long-term prospects in antiviral drug development.

1 year ago

#NNVC NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company

www.stocktitan.net/news/NNVC/nano-viricides...

1 0 0 0

Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan NanoViricides (NNVC) announces its drug candidate NV-387 as a potential treatment for the ongoing measles outbreak, addressing HHS Secretary Kennedy's concern about the lack of approved antivirals. The broad-spectrum antiviral has shown effectiveness against various viruses that use heparan sulfate proteoglycans (HSPG) during cell infection.The company believes NV-387 could be effective against measles based on two key factors: (1) studies indicating measles virus uses HSPG during cell infection, and (2) its success in treating RSV, which belongs to the same virus family as measles. NanoViricides proposes an investigator-initiated clinical trial to evaluate NV-387 as a measles treatment within FDA regulatory framework.The announcement comes amid concerns about vaccine effectiveness against new measles variants, with the current Texas outbreak showing that even some vaccinated children are being hospitalized. The outbreak strain (genotype D.8) differs from the vaccine strain (genotype A), highlighting the need for effective treatment options.

1 year ago

#NNVC Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan

www.stocktitan.net/news/NNVC/measles-outbre...

0 0 0 0

NanoViricides, Inc. Has Filed its Quarterly Report NanoViricides (NYSE:NNVC) has filed its Q4 2024 quarterly report, highlighting its progress with NV-387, a broad-spectrum antiviral drug. The company reported $3.96M in cash and equivalents, with $7.17M in net property and equipment assets. Total current liabilities were $1.18M.The company is preparing for Phase II clinical trials of NV-387 to treat MPox infection in Central Africa, where clinical trial sites have been identified. NV-387 successfully completed Phase Ia/Ib trials with no adverse events. The drug has shown promising results against various viruses, including Bird Flu H5N1, RSV, Influenza, and MPox.However, NNVC reported insufficient funding to continue operations through February 14, 2026, for planned objectives. The company raised approximately $4M through an ATM offering and has access to a $3M credit line from its founder.

1 year ago

#NNVC NanoViricides, Inc. Has Filed its Quarterly Report

www.stocktitan.net/news/NNVC/nano-viricides...

0 0 0 0